Search Results - subject:"Chronic obstructive"

A 1-Year Prospective Cost-Effectiveness Analysis of Roflumilast for the Treatment of Patients with Severe Chronic Obstructive Pulmonary Disease

Rutten-van Molken, Maureen P.M.H.; van Nooten, Floortje E. - In: PharmacoEconomics 25 (2007) 8, pp. 695-711

Rationale: Roflumilast is an oral, once-daily phosphodiesterase IV (PDE4) inhibitor under investigation for chronic … obstructive pulmonary disease (COPD). This study investigated the cost effectiveness of roflumilast in patients with severe to …

Persistent link: https://www.econbiz.de/10005449249

Ökonomische Analyse der Arzneimitteltherapie chronisch-obstruktiver Atemwegskrankheiten : Grundlagen und methodische Ansätze

Hanpft, Reinhard - 1989

Persistent link: https://www.econbiz.de/10013432123

Doll, Helen; Miravitlles, Marc - In: PharmacoEconomics 23 (2005) 4, pp. 345-363

bronchitis (CB) or chronic obstructive pulmonary disease (COPD). The aim of this review is to examine the use of HR …

Persistent link: https://www.econbiz.de/10005590363

Development of an Economic Model to Assess the Cost Effectiveness of Treatment Interventions for Chronic Obstructive Pulmonary Disease

Spencer, Michael; Briggs, Andrew H.; Grossman, Ronald F.; … - In: PharmacoEconomics 23 (2005) 6, pp. 619-637

Objective: To develop a Markov model that allows the cost effectiveness of interventions in patients with chronic … obstructive pulmonary disease (COPD) to be estimated, and to apply the model to investigate the cost effectiveness of an inhaled …

Persistent link: https://www.econbiz.de/10005590511

Cost Effectiveness of Budesonide/Formoterol in a Single Inhaler for COPD Compared with Each Monocomponent Used Alone

Lofdahl, Claes-Goran; Ericsson, Asa; Svensson, Klas; … - In: PharmacoEconomics 23 (2005) 4, pp. 365-375

budesonide and formoterol monotherapies, and placebo, in a multinational study in patients with chronic obstructive pulmonary … disease (COPD), National Heart, Lung and Blood Institute (NHLBI)/WHO Global Initiative for Chronic Obstructive Lung Disease …

Persistent link: https://www.econbiz.de/10005449293

Utilization and Medical Care Expenditures in Patients with Chronic Obstructive Pulmonary Disease: A Managed Care Claims Data Analysis

Yu-Isenberg, Kristina S.; Vanderplas, Ann; Chang, Eunice Y. - In: Disease Management and Health Outcomes 13 (2005) 6, pp. 405-412

Objective: To estimate annual healthcare utilization and expenditures for patients with chronic obstructive pulmonary …

Persistent link: https://www.econbiz.de/10005243052

Pulmonary Rehabilitation Programs: Improving Outcomes in Elderly Patients with COPD

Leuppi, Jorg D.; Bingisser, Roland M. - In: Disease Management and Health Outcomes 12 (2004) 5, pp. 281-284

widespread application of these programs limited scientific data is available on the subject, except in chronic obstructive …

Persistent link: https://www.econbiz.de/10005590124

Healthcare Costs with Tiotropium Plus Usual Care versus Usual Care Alone Following 1 Year of Treatment in Patients with Chronic Obstructive Pulmonary Disorder (COPD)

Friedman, Mitchell; Menjoge, Shailendra S.; Anton, Susan F. - In: PharmacoEconomics 22 (2004) 11, pp. 741-749

Background: Healthcare costs for chronic obstructive pulmonary disease (COPD) have continued to increase with the …

Persistent link: https://www.econbiz.de/10005449072

Methods to Analyse Cost Data of Patients Who Withdraw in a Clinical Trial Setting

Oostenbrink, Jan B.; Al, Maiwenn J.; Rutten-van Molken, … - In: PharmacoEconomics 21 (2003) 15, pp. 1103-1112

comparing patients with chronic obstructive pulmonary disease receiving either tiotropium bromide or ipratropium bromide. The …

Persistent link: https://www.econbiz.de/10005404859

Disease-Specific Self-Management Programs in Patients with Advanced Chronic Obstructive Pulmonary Disease: A Comprehensive and Critical Evaluation

Bourbeau, Jean - In: Disease Management and Health Outcomes 11 (2003) 5, pp. 311-319

Chronic obstructive pulmonary disease (COPD) is a long-term illness. As the disease progresses, it become more complex …

Persistent link: https://www.econbiz.de/10005590127